Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pill for HCV - myth or foreseeable future?

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2014

Jaroszewicz Jerzy, Flisiak Robert, Dusheiko Geoffrey

Abstract excerpt

Weekly injections with pegylated-IFNa (PegIFN) combined with daily ribavirin (RBV) are still the standard of care for chronic hepatitis C in most of the world. Sustained virological response (SVR) of 40-50% for patients infected with HCV genotypes (GT) 1 or 4 and 70-90% for genotypes 2-3 are achi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Treatment Outcome

Source

Identifiers

PMID: 23998627
DOI: 10.1111/liv.12294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23998627-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

A pill for HCV - myth or foreseeable future?PMID 23998627Read ↗

Future perspectives: towards interferon-free regimens for HCV.Semantic proximity Read ↗

Interferon-free regimens: the near future, the likely and the not so likely.Semantic proximity Read ↗

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.Semantic proximity Read ↗

Interferon-free therapy for hepatitis C: The hurdles amid a golden era.Semantic proximity Read ↗

Why I do not treat patients for mild disease.Semantic proximity Read ↗

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?Semantic proximity Read ↗

Interferon-Free Strategies without a Nucleoside/Nucleotide AnalogueSemantic proximity Read ↗

Why do I treat my patients with mild hepatitis C?Semantic proximity Read ↗

On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.